Yasuda, Hiroyuki

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Pulmonary Medicine) (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor

External Links

Career 【 Display / hide

  • 2001.04
    -
    2005.03

    慶應義塾大学医学部内科学教室

  • 2005.04
    -
    2010.12

    慶應義塾大学医学部内科学(呼吸器)

  • 2011.01
    -
    2012.03

    Beth Israel Deaconess Medical Center, Harvard Medical School

  • 2012.04
    -
    Present

    慶應義塾大学医学部内科学(呼吸器)

Academic Background 【 Display / hide

  • 2001

    慶応義塾大学, 医学部

    Graduated

Academic Degrees 【 Display / hide

  • 医学博士, 慶應義塾大学, Dissertation

 

Research Areas 【 Display / hide

  • Molecular biology (腫瘍生物学)

  • Cell biology (細胞生物学)

  • Respiratory organ internal medicine (肺癌)

  • Respiratory organ internal medicine (トランスレーショナル研究)

Research Keywords 【 Display / hide

  • オルガノイド

  • トランスレーショナル研究

  • バイオバンク

  • 細胞生物学

  • 肺癌

display all >>

 

Papers 【 Display / hide

  • HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.

    Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y

    Thoracic cancer  2021.01

    ISSN  1759-7706

  • Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model

    Kobayashi K., Terai H., Yasuda H., Hamamoto J., Hayashi Y., Takeuchi O., Mitsuishi Y., Masuzawa K., Manabe T., Ikemura S., Kawada I., Suzuki Y., Soejima K., Fukunaga K.

    Biochemical and Biophysical Research Communications (Biochemical and Biophysical Research Communications)  534   1 - 7 2021.01

    ISSN  0006291X

     View Summary

    © 2020 The Authors The development of molecular targeted therapy has improved clinical outcomes in patients with life-threatening advanced lung cancers with driver oncogenes. However, selective treatment for KRAS-mutant lung cancer remains underdeveloped. We have successfully characterised specific molecular and pathological features of KRAS-mutant lung cancer utilising newly developed cell line models that can elucidate the differences in driver oncogenes among tissues with identical genetic backgrounds. Among these KRAS-mutation-associated specific features, we focused on the IGF2-IGF1R pathway, which has been implicated in the drug resistance mechanisms to AMG 510, a recently developed selective inhibitor of KRAS G12C lung cancer. Experimental data derived from our cell line model can be used as a tool for clinical treatment strategy development through understanding of the biology of lung cancer. The model developed in this paper may help understand the mechanism of anticancer drug resistance in KRAS-mutated lung cancer and help develop new targeted therapies to treat patients with this disease.

  • An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.

    Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, Ebisudani T, Shimokawa M, Takano A, Takahashi S, Ohta Y, Nanki K, Igarashi R, Ishimaru K, Ishida H, Sukawa Y, Sugimoto S, Saito Y, Maejima K, Sasagawa S, Lee H, Kim HG, Ha K, Hamamoto J, Fukunaga K, Maekawa A, Tanabe M, Ishihara S, Hamamoto Y, Yasuda H, Sekine S, Kudo A, Kitagawa Y, Kanai T, Nakagawa H, Sato T

    Cell  2020.10

    ISSN  0092-8674

  • SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer Cells.

    Terai H, Hamamoto J, Emoto K, Masuda T, Manabe T, Kuronuma S, Kobayashi K, Masuzawa K, Ikemura S, Nakayama S, Kawada I, Suzuki Y, Takeuchi O, Suzuki Y, Ohtsuki S, Yasuda H, Soejima K, Fukunaga K

    Molecular cancer research : MCR  2020.10

    ISSN  1541-7786

  • Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: A multicenter retrospective study.

    Ishii M, Terai H, Kabata H, Masaki K, Chubachi S, Tateno H, Nakamura M, Nishio K, Koh H, Watanabe R, Ueda S, Terashima T, Suzuki Y, Yagi K, Miyao N, Minematsu N, Inoue T, Nakachi I, Namkoong H, Okamori S, Ikemura S, Kamata H, Yasuda H, Kawada I, Hasegawa N, Fukunaga K, Keio COVID-19 Research Consortium (K-CORC) and the Keio Donner Project Team.

    The Journal of infection  2020.09

    ISSN  0163-4453

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Reviews, Commentaries, etc. 【 Display / hide

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 肺癌オルガノイドライブラリー統合解析による癌の不均一性の解明と新規治療標的同定

    2020.04
    -
    2022.03

    日本医療研究開発機構(AMED), 次世代がん医療創生研究事業, 安田浩之, Principal Investigator

  • 肺癌オルガノイドを用いた治療後期肺癌の悪性度の本態解明

    2019.04
    -
    2022.03

    日本医療研究開発機構(AMED), 革新的がん医療実用化研究事業, 安田浩之

  • 肺癌オルガノイドライブラリーを用いたprecision medicineの確立と新規治療標的の同定

    2018.11
    -
    2020.03

    日本医療研究開発機構(AMED), 次世代がん医療創生研究事業, 安田浩之, No Setting

  • 難治性あるいは希少肺癌克服のための肺癌基礎研究臨床応用システムの構築

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 安田 浩之, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • Clinical application of Imaging Mass-spectrometry in cancer fileld

    2015.04
    -
    2017.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 安田 浩之, Grant-in-Aid for Challenging Exploratory Research, Principal Investigator

     View Summary

    The prognosis of cancer patients is poor. To improve the prognosis of cancer patients, variable approaches are necessary. Imaging mass-spectrometry (IMS) is a novel technology, which enables one to viisualize the distribution of hundreds of metabloite in tissues. Using this novel technology, we treid to clarify the mechansims of efficacy of some anti-cancer agents. We focused on anti-angiogenic agents such as nintedanib or bevacizumab. We partly clarified the mechanisms of efficacy of these agents by in vivo experiments with IMS. The findings will help developing an effective and appropriate treatement using anti-angiogenic agents.

display all >>

Awards 【 Display / hide

  • 武田科学振興財団研究助成金(医学系研究継続助成)

    2019

    Type of Award: Other Awards

  • 研究奨励賞 日本肺癌学会

    2018

    Type of Award: Awards of National Conference, Council and Symposium

  • 武田科学振興財団研究助成金(医学系研究)

    2016

    Type of Award: Other Awards

  • 第55回 日本呼吸器学会 学会奨励賞

    2015

  • 日本肺癌学会 若手奨励賞

    2015

display all >>

 

Courses Taught 【 Display / hide

  • PHARMACOLOGY

    2021

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2021

  • CASE STUDIES OF INTERNAL MEDICINE

    2021

  • PHARMACOLOGY

    2020

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2020

display all >>